Mineralys Therapeutics, Inc.
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$154.7M
- Total assets
- $661.8M
- Market cap
- $2.1B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $170.6M
- Operating income
- -$170.6M
- Income tax
- $0
- Net income
- -$154.7M
- EPS (basic)
- $-2.29
- EPS (diluted)
- $-2.29
Balance sheet
- Total assets
- $661.8M
- Current assets
- $661.4M
- Total liabilities
- $15.1M
- Current liabilities
- $15.1M
- Shareholders’ equity
- $646.7M
Cash flow
- Operating cash flow
- -$142.4M
- Investing cash flow
- -$389.8M
- Financing cash flow
- $591.0M
- Net cash flow
- $58.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.1B
- EPS (diluted)
- $-2.29
- Shares outstanding
- 92.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 10, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $154.7M.
- Trading 52% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Mineralys Therapeutics, Inc..
Write a review
News about Mineralys Therapeutics, Inc.
News & sentiment via Polygon.io
